Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015 USD ($) Segment CreditFacility shares	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($) shares	Dec. 31, 2012 USD ($)	Dec. 31, 2002 USD ($) shares	May. 31, 2002 USD ($)
Significant Accounting Policies [Line Items]
Amounts classified as short-term deferred revenue	$ 0	$ 0
Amounts classified as long-term deferred revenue	0	0
In-process research and development expense	24,347,815
Assets measured at fair value on a nonrecurring basis	0	0
Liabilities measured at fair value on a nonrecurring basis	0	0
Fair value of investment transferred from level 1 to level 2	252,222
Long-lived assets	277,714	407,738
Impairment charges	0	0	$ 0
Total debt issuance costs	80,983	108,180		$ 421,715
Debt issue costs, current	32,619	43,616
Debt issue costs, long-term	48,364	64,564
Goodwill	8,982,000	8,982,000
Goodwill impairment charges	0	0	0
Approved repurchase of common stock						$ 3,000,000
Common stock surrendered to pay the exercise price | shares					1,047,707
Repurchase shares of common stock, value			$ 632,755		$ 891,274
Option cost	$ 1,524,029	$ 1,524,029
Facility under noncancellable operating lease agreement | CreditFacility	1
Number of operating segment | Segment	1
Curis Royalty [Member]
Significant Accounting Policies [Line Items]
Total debt issuance costs				206,715
BioPharma-II [Member]
Significant Accounting Policies [Line Items]
Total debt issuance costs				215,000
Amended and Restated 2010 Plan [Member]
Significant Accounting Policies [Line Items]
Common stock surrendered to pay the exercise price | shares	1,222,846		175,139
Option cost	$ 1,524,029		$ 632,755
Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available-for-sale securities weighted average maturity	4 months 6 days	4 months 3 days
Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available-for-sale securities weighted average maturity		13 months 24 days
Minimum [Member] | Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	1 month	1 month
Minimum [Member] | Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range		2016-01
Maximum [Member] | Short-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range	12 months	12 months
Maximum [Member] | Long-term Investments [Member]
Significant Accounting Policies [Line Items]
Available for sale securities maturity period range		2016-05
Genentech IAP License [Member]
Significant Accounting Policies [Line Items]
In-process research and development expense	$ 24,347,815			$ 9,500,000